



Clinical and angiographic outcomes of ultrathin biomime versus thicker ultimaster stents during primary percutaneous coronary interventions

Magdy Algowhary¹, Marwan S. Mahmoud¹, Amr Ahmed Abdelnazeer^{1*}, Salwa Roshdy Demitry¹, Mahmoud Abdelsabour¹

Abstract

Objectives: The aim of this study was to examine the safety and effectiveness of the Biomime sirolimus-eluting stent (SES) versus a thicker-strut Ultimaster SES in cases presenting with ST-elevation myocardial infarction (STEMI) who were subjected to primary PCI.

Methods: For this prospective, single-center, randomized, open-label, active-controlled, noninferiority trial, a sample of 370 STEMI patients were enrolled and randomly assigned (1:1) to be delivered Biomime SES and Ultimaster SES.

Results: Biomime was non-inferior to Ultimaster for target vessel failure (TVF) at one year at 20 (10.9%) vs. 14 (8.4%) relative risk (RR) (95% confidence interval [CI]: 1.296 [0.677–2.482], $p = 0.432$; P for non-inferiority [PNI] = 0.059). Additionally, there are no significant differences regarding major adverse cardiovascular events (MACE), which occurred at a rate of 30 (16.4%) in the Biomime group vs. 18 (10.5%) in the Ultimaster group; RR (95% CI): 1.512 (0.877–2.61), $p = 0.133$; (PNI) < 0.001). Angiographic follow-up revealed no significant difference in in-stent late lumen loss (LLL), at 0.34 ± 0.4 mm vs. 0.36 ± 0.4 mm; Diff (95% CI): -0.02 (-0.14 to 0.10), $p = 0.756$; PNI < 0.001).

Conclusion: In STEMI cases subjected to primary PCI, the Biomime SES was non-inferior to Ultimaster SES at one-year follow-up. Longer-term studies are warranted to confirm these findings.

Keywords

ST-elevation myocardial infarction, Biomime, Ultimaster, Ultrathin Stents, Primary Percutaneous Coronary Intervention

Rezumat

Obiective: Scopul lucrării a fost de a examina siguranța și eficacitatea stentului Biomime cu eliberare de sirolimus (SES) versus un SES Ultimaster cu strut mai gros în cazurile care prezintă infarct miocardic cu supradenivelare ST (STEMI) care au fost supuși intervenției coronariene percutanate primare.

Metode: Acest studiu prospectiv, monocentric, randomizat, deschis, controlat activ, de non-inferioritate. Un eșantion de 370 de pacienți cu STEMI a fost înrolat și repartizat aleatoriu (1:1) la Biomime SES și Ultimaster SES. Biomime SES și Ultimaster SES au fost administrate la 370 de pacienți cu STEMI în mod aleatoriu (1:1).

Rezultate: Biomime a fost non-inferior Ultimasterului în ceea ce privește insuficiența vasului țintă (TVF) la un an (20 (10,9%) vs. 14 (8,4%); risc relativ (RR) (interval de încredere 95% (IC): 1,296 (0,677–2,482), $p=0,432$; P pentru non-inferioritate PNI =0,059). În plus, nu există diferențe semnificative în ceea ce privește evenimentele cardiovasculare adverse majore (MACE) (30 (16,4%) în Biomime vs. 18 (10,5%) în Ultimaster; RR (IC 95%): 1,512 (0,877–2,61), $p=0,133$; (PNI) <0,001). Urmărirea angiografică nu a relevat nicio diferență semnificativă în ceea ce privește pierderea tardivă a lumenului în stent ($0,34 \pm 0,4$ mm vs. $0,36 \pm 0,4$ mm; Diferența (95%)). CI): -0,02 (-0,14 la 0,10), $p=0,756$; PNI <0,001).

Concluzie: În cazurile de STEMI supuse intervenției coronariene percutanate primare, Biomime SES a fost non-inferior SES Ultimaster la o an de urmărire. Sunt necesare studii pe termen lung pentru a confirma aceste constatări.

Cuvinte cheie

infarct miocardic cu supradenivelare de ST, Biomime, Ultimaster, stenturi ultrasubțiri, intervenție coronariană percutanată primară

Introduction

The Biomime (Meril Life Sciences, India) is an ultra-thin (65 μ m) cobalt-chromium stent with a hybrid design offering open-cell mid-section for flexibility and closed-cell ends for stability. It elutes sirolimus (1.25 μ g/mm²), an antiproliferative drug, over 30–40 days post-implantation. [1, 2]

Ultra-thin (< 70 μ m) DES have been shown to improve outcomes compared with second-generation DES due to better deliverability;

reduced vessel injury; decreased inflammation and side-branch flow disturbance; and faster endothelialization [2]. They also reduce the risk of in-stent restenosis, thereby decreasing the risk of angiographic and clinical restenosis [2].

The Ultimaster SES (Terumo, Japan) uses the Kaname platform with an abluminal bioresorbable polymer (PDLLA-PCL) coating, delivering sirolimus (3.9 μ g/mm) with complete polymer degradation in four months. [3, 4]

Our study aimed to examine the safety and effectiveness of the Biomime sirolimus-eluting stent (SES) versus a thicker-strut Ultimaster SES in cases presenting with ST-elevation myocardial infarction (STEMI) who were subjected to primary PCI (PPCI).

*Corresponding author: Amr Ahmed Abdelnazeer, Cardiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt; E-mail address: amrnazir@aun.edu.eg

¹Cardiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

Methods

Study design and population: This was a prospective, single-center, randomized, open-label, active-controlled non-inferiority trial conducted at Assiut University Hospital. From October 1, 2020, to September 30, 2022, 370 STEMI patients who were subjected to PPCI were included in the study and followed up on for one year.

Inclusion criteria included cases suffering from STEMI that had been diagnosed according to current guidelines. [5, 6]

This study was executed in compliance with the ethical standards of the institutional and/or national research committee (IRB no: 04-2024-100305) and the guidelines of the 1964 Helsinki Declaration, along with its later amendments or similar ethical standards. All study participants granted their informed consent.

Exclusion criteria included left ventricular ejection fraction (LVEF) of less than 30%; Killip class > I at presentation; extreme vessel tortuosity (≥ 2 consecutive curves of exceeding 180° in one of the major coronary arteries) [6]; lesion angulation exceeding 45° ; severe calcification [7, 8]; bifurcation lesions with side-branch diameter exceeding 2 mm; mechanical complications of STEMI; or severe comorbidities, such as end-stage renal disease or malignancy.

Clinical and angiographic follow-up: Clinical follow-up was conducted at 30 days and one-year post-procedure. Electrocardiograms (ECGs) were obtained before and immediately after re-perfusion, 90 minutes post-flow restoration, and as needed. Echocardiography was performed at discharge and after one year to evaluate LVEF, wall motion score index (WMSI), and degree of mitral regurgitation. Angiographic follow-up was scheduled at one year to assess late lumen loss (LLL), binary restenosis, and minimal lumen diameter (MLD).

Dual antiplatelet treatment (DAPT) composed of aspirin (at a dosage of 75–150 mg daily) and clopidogrel (75 mg daily) or ticagrelor (180 mg/daily) prescribed for one year or longer. Beyond one year, aspirin was recommended indefinitely.

Study endpoints and definitions: The primary clinical endpoint was target vessel failure (TVF), which is determined by cardiac death (target vessel cannot be excluded); target vessel myocardial infarction (MI); or clinically induced target vessel revascularization (CD-TVR). [2, 9]

Secondary clinical endpoints: Secondary clinical endpoints included Major Adverse Cardiac events (MACE), including myocardial cardiac death, myocardial infarction, and CD-TVR.

Cardiac death was outlined as death due to myocardial infarction, arrhythmia, cardiac failure,

cardiac arrest, procedural complications, or unknown causes. [2] Major bleeding and stent thrombosis (ST) were also secondary clinical endpoints, as established by the Academic Research Consortium (ARC) criteria. [9]

Angiographic endpoints: In stent, LLL was the primary endpoint. In-stent and in-segment stenosis, MLD, and restenosis rate ($> 50\%$ diameter stenosis) [2] were the secondary angiographic endpoints.

Quantitative coronary angiography (QCA): QCA was performed at baseline, following the procedure, in conjunction




Figure 1 - Patient enrollment and disposition.

with the one-year follow-up. It was analyzed using independent core laboratory using automated edge detection. Paired QCA was performed for each target lesion within the stent and nearby segments, including 5-mm margins proximally and distally from the stent. [10]

Sample size calculation: Sample size calculation was performed via G*Power 3 software. To identify an effect size of 0.5 (expected TVF rates of 7.2% in the Biomime group vs. 3.5% in the Ultimaster group), a minimum of 146 patients (1:1 randomization) was needed, with a non-inferiority margin of 5%, $\alpha = 0.01$, and 95% power. LLL was expected to be 0.2 ± 0.5 mm for Biomime vs. 0.41 ± 0.5 mm for Ultimaster, requiring 140 patients (70 patients in each group) for angiographic endpoints, with an additional 20% allowance for drop-out.

Statistical analysis: Statistical analyses were carried out using R software. Continuous variables were compared via a Student's t-test or Mann-Whitney U test (if not normally distributed). Categorical-variable analysis was carried out via the chi-square test. TVF and MACE-free survival analysis were assessed via the Kaplan-Meier method. A p-value < 0.05 was regarded as statistically significant.

Results: A total of 380 STEMI patients were included and randomly assigned (1:1) to Biomime SES or Ultimaster SES.

No significant difference was noticed between the groups regarding baseline clinical characteristics, ECG findings, the percentage of troponin elevation, the incidence of in-hospital arrhythmias, or echocardiographic parameters, other than a higher WMSI in the Ultimaster group. Moderate mitral regurgitation (grade II/IV) was observed more frequently in the Biomime group (11%) than in the Ultimaster group (4%), resulting in significant differences ($P = 0.039$). The use of P2Y12 inhibitors was comparable between the two groups.

Proximal lesion location, baseline TIMI flow, and final TIMI flow rates were the same in both groups. Pre-dilatation was performed significantly more often in the Ultimaster group (78%) than in the Biomime group (66%), with a statistically significant difference ($P = 0.016$). No differences were documented between the groups post-dilatation in maximum inflation pressure or overall stent diameter. However, stent sizes ≤ 2.75 mm were more commonly used in the

Table 1 - Baseline characteristics, ECG, ECHO, and laboratory findings in Biomime and Ultimaster groups

		Biomime (N=183)	Ultimaster (N=166)	P
Age (years)		57±11	56±11	0.390
Sex	Male	137 (74.9%)	130 (78.3%)	0.448
	Female	46 (25.1%)	36 (21.7%)	
DM		53 (29.0%)	60 (36.1%)	0.152
HTN		49 (26.8%)	55 (33.1%)	0.195
Smoking		101(55.2%)	86 (51.8%)	0.527
Dyslipidemia		131(71.6%)	115 (69.3%)	0.637
Total ischemic time (hours)		5.6±3.8	5.4±3.1	0.600
Door to balloon (min)		36±12	38±11	0.233
P2Y12 inhibitors	Ticagrelor	170 (92.9%)	161(97.0%)	0.084
	Clopidogrel	137 (7.1%)	5 (3.0%)	
GPIIb/IIIa inhibitors		49 (26.8%)	36 (21.7%)	0.269
Site of infarction	Anterior	95 (51.9%)	97 (58.4%)	0.295
	Inferior	60 (32.8%)	42 (25.3%)	
	Inferiorright	14 (7.7%)	7 (4.2%)	
	Inferolateral	2 (1.1%)	5 (3.0%)	
	Infero-posterior	8 (4.4%)	8 (4.8%)	
	Posterior	2 (1.1%)	2 (1.2%)	
	Lateral	2 (1.1%)	5 (3.0%)	
ST resolution		132 (72.1%)	121 (72.9%)	0.874
In-hospital arrhythmias	VT	1 (0.5%)	2 (1.2%)	0.338
	VF	4 (2.2%)	1 (0.6%)	
	AF	5 (2.7%)	3 (1.8%)	
	Junctional	1 (0.5%)	0 (0.0%)	
	CHB	5 (2.7%)	1 (0.6%)	
	None	167 (91.3%)	159 (95.8%)	
LVEF		50±8	49±8	0.276
WMSI		1.42 ±0.2	1.47±0.2	0.051
MR	0	124 (67.8%)	112 (67.5%)	0.039*
	I	38 (20.8%)	44 (26.5%)	
	II	20 (10.9%)	6 (3.7%)	
	III	0 (0.0%)	2 (1.2%)	
	IV	1 (0.5%)	2 (1.2%)	
Troponin (ng/dl)		22±22	20±19	0.450

Data are presented as mean ± SD or frequency (%). *Significant P value < 0.05. DM: diabetes mellitus, HTN: hypertension, GPIIb/IIIa: glycoprotein IIb/IIIa inhibitors, AF: atrial fibrillation; CHB: complete heart block; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; SD: standard deviation; VF: ventricular fibrillation; VT: ventricular tachycardia; WMSI: wall motion score index.

Ultimaster group than the Biomime one (P < 0.001), and longer stents tended to be used in the Biomime group than in the Ultimaster group (P < 0.001).

Baseline pre-stenting measurements, including MLD, percentage diameter stenosis (% DS), and reference vessel diameter (RVD), were the same between both groups. Post-procedure QCA revealed comparable acute luminal gain following stent implantation in both groups. The one-year follow-up showed a non-significant difference in in-stent LLL between the Biomime and Ultimaster groups (0.34 ±

Table 2 - Baseline lesion and procedural characteristics of Biomime and Ultimaster groups

		Biomime (N=183)	Ultimaster (N=166)	P
Number of diseased vessels	One	122 (67.0%)	99 (59.0%)	0.208
	Two	36 (20.0%)	46 (28.0%)	
	Three	25 (13.0%)	21 (13.0%)	
Infarcted related artery	LAD	93 (50.8%)	99 (59.6%)	0.155
	LCx	13 (7.1%)	19 (11.4%)	
	RCA	68 (37.2%)	39 (23.5%)	
	Diagonal	1 (0.5%)	2 (1.2%)	
	OM	4 (2.2%)	2 (1.2%)	
	PDA	2 (1.1%)	3 (1.8%)	
	Ramus	2 (1.1%)	2 (1.2%)	
Site of occlusion	Proximal	118 (64.5%)	106 (63.9%)	0.650
	Mid	56 (30.6%)	48 (28.9%)	
	Distal	9 (4.9%)	12 (7.2%)	
Baseline TIMI flow	0	161 (88.0%)	128 (77.1%)	0.062
	I	14 (7.7%)	24 (14.5%)	
	II	4 (2.2%)	6 (3.6%)	
	III	4 (2.2%)	8 (4.8%)	
Post procedure TIMI flow	0	1 (0.5%)	0 (0.0%)	0.136
	I	5 (2.7%)	0 (0.0%)	
	II	13 (7.1%)	12 (7.2%)	
	III	164(89.6%)	154(92.8%)	
Pre-dilatation		121 (66.1%)	129 (77.7%)	0.016*
Post-dilatation		36 (19.7%)	27 (16.3%)	0.409
Stent length (mm)		31.7±7.7	28.5±6.9	<0.001*
Stent diameter (mm)		3.3±0.4	3.2±0.5	0.203
Stent diameter (mm)	2.25	1 (1.0%)	1 (1.0%)	<0.001*
	2.5	2 (1.0%)	10 (6.0%)	
	2.75	16 (9.0%)	37 (22.0%)	
	3.00	79 (42.0%)	45 (27.0%)	
	3.5	69 (38.0%)	52 (31.0%)	
	4.00	16 (9.0%)	21 (13.0%)	
Max. inflation (atm)		15.2±2.5	14.9±2.4	0.281

Data are presented as mean ± SD or frequency (%). LAD: left anterior descending; LCx: left circumflex; RCA: right coronary artery; OM: obtuse marginal; PDA: posterior descending artery; TIMI: thrombolysis in myocardial infarction.

0.4 mm vs. 0.36 ± 0.4 mm, difference [95% CI]: -0.02 [-0.14 to 0.10], P = 0.756, and PNI [P for non-inferiority] < 0.001) as shown in Figure 2's central illustration. Similarly, the restenosis rate showed non-significant differences between both groups, with 14 cases (16.7%) in the Biomime group and 11 cases (14.3%) in the Ultimaster group (RR [95% CI]: 1.154 [0.529 – 2.47], P = 0.677, and PNI = 0.001). These findings support the non-inferiority of the Biomime stent compared to the Ultimaster stent.

At one year, the Biomime stent proved its non-inferiority to the Ultimaster stent with regard to TVF and MACE. The TVF rate showed non-significant increases in the Biomime group (20 patients, 10.9%) compared to the Ultimaster group (14 patients, 8.4%) (RR [95% CI]: 1.296 [0.677–2.482], P = 0.432, and PNI = 0.059). Similarly, MACE appeared in 30 cases (16.39%) in the Biomime group, compared to 18 cases (10.48%) in the Ultimaster group (RR [95% CI]: 1.512 [0.877–2.61], P = 0.133, and PNI < 0.001).

CENTRAL ILLUSTRATION: Kaplan-Meier Cumulative Event Curves for the Main Endpoint, A) Target Vessel Failure, B) MACE and C) MI at 1-Year Follow-Up. D) Cumulative frequency distribution (CFD) curves for in-stent late lumen loss




Figure 2 - Central illustration: Kaplan-Meier cumulative event curves for the main endpoint. A) Target Vessel Failure, B) MACE, and C) MI at one-year follow-up. D) Cumulative frequency distribution (CFD) curves for in-stent late lumen loss. MACE: major adverse cardiac events, MI: myocardial infarction.

Table 3 - Procedural quantitative measures at baseline, immediately post procedure, and at follow up in Biomime and Ultimaster groups.

		Biomime (n=183)	Ultimaster (n=166)	Diff and (95%CI)	P
Baseline	RVD	2.79±0.4	2.76±0.5	0.03 (-0.05–0.05)	0.599
	MLD	0.79±0.23	0.76±0.26	0.03 (-0.02–0.09)	0.186
	DS	71.03±8.2	72.33±8.6	-1.3 (-3.07–0.48)	0.151
Immediately post procedure					
	RVD	3.21±0.4	3.14±0.46	0.06 (-0.03–0.15)	0.166
MLD	In-stent	2.57±0.4	2.55±0.5	0.02 (-0.07–0.12)	0.653
	In-segment	2.32±0.4	2.33±0.5	-0.01 (-0.11–0.08)	0.817
DS	In-stent	19.77±7.7	19.10±9.6	0.67 (-1.15–2.49)	0.470
	In-segment	27.80±7.9	26.21±9.9	1.59 (-0.29–3.47)	0.096
Acute gain	In-stent	1.78±0.4	1.79±0.5	-0.01 (-0.1–0.08)	0.796
	In-segment	1.52±0.4	1.57±0.5	-0.05 (-0.14–0.05)	0.346
		N = 84	N = 78		
Follow-Up					
	RVD	3.04±0.4	3.05±0.4	-0.01(-0.13–0.12)	0.940
MLD	In-stent	2.24±0.6	2.28±0.7	-0.04 (-0.24–0.16)	0.685
	In-segment	2.02±0.6	2.08±0.6	-0.06 (-0.25–0.14)	0.549
DS	In-stent	27.5±4.6	25.7±16.6	1.76 (-3.09–6.36)	0.473
	In-segment	34.8±14.9	32.1±15.9	2.77 (-2.13–7.48)	0.273
LLL	In-stent	0.34±0.4	0.36±0.4	-0.02 (-0.14–0.10)	0.756
	In-segment	0.31±0.4	0.35±0.4	0.01 (-0.14–0.10)	0.876
Re-stenosis		14 (16.7%)	11 (14.3%)	1.154 (0.529–2.47)	0.677

Data are presented as mean ± SD. CI: confidence interval; RVD: reference vessel diameter; MLD: minimal lumen diameter; DS: diameter stenosis; LLL: late lumen loss.

Table 4 - Clinical endpoints at 30 days and at 12 months in Biomime and Ultimaster groups.

	Biomime (n = 183)	Ultimaster (n = 166)	P
30 days			
All-cause death	1 (0.5%)	0 (0.0%)	0.340
All MI	2 (1.1%)	1 (0.6%)	0.620
Stroke	0 (0.0%)	1 (0.6%)	0.293
Major bleeding	0 (0.0%)	0 (0.0%)	-----
Definite stent thrombosis	2 (1.1%)	1 (0.6%)	0.620
Composite (all-cause death, re-MI, stroke, major bleeding, definite ST)	3 (1.6%)	2 (1.2%)	0.733
One year			
All cause death	5 (2.7%)	0 (0.0%)	0.032
Cardiac death	1 (0.5%)	0 (0.0%)	0.340
Undetermined death	4 (2.2%)	0 (0.0%)	0.055
Definite ST	8 (4.4%)	3 (1.8%)	0.171
MI not clearly attributable to a non-target vessel	4 (2.2%)	3 (1.8%)	0.558
Major bleeding	0 (0.0%)	1 (0.6%)	0.293
Heart failure	4 (2.2%)	1 (0.6%)	0.214
CD-TLR	9 (4.9%)	9 (5.4%)	0.832
C-TVR (including CD-TLR)	9 (4.9%)	9 (5.4%)	0.832
Total MACE	30 (16.39%)	18 (10.48%)	0.133
Target Vessel failure	20 (10.9%)	14 (8.4%)	0.432

Data are presented as mean $\pm$ SD or frequency (%). MI: myocardial infarction; ST: stent thrombosis; CD-TLR: clinically driven-target lesion revascularization; CD-TVR: clinically driven-target vessel revascularization; MACE: major adverse cardiac events.

Both the Biomime and the Ultimaster group showed a slight, but not significant, increase in the incidence of ST at one year. Due to the non-inferiority design of the study, however, results were inconclusive.

The Kaplan-Meier survival curves in Figure 2's central illustration demonstrate comparable survival outcomes between the two stents. Subgroup analysis favored the use of Ultimaster in small-vessel interventions.

Discussion

This study compared the novel ultra-thin Biomime SES to the thicker Ultimaster stent in STEMI patients subjected to PPCI. The Biomime sirolimus eluting stent (SES) demonstrated non-inferiority to Ultimaster SES at one year regarding TVF and MACE. Angiographic outcomes, including LLL and restenosis rate, were the same between the two groups. The cumulative rates of all-cause mortality, recurrent infarction, unplanned ischemia-related artery revascularization, stroke, definite stent thrombosis, and major bleeding at one year did not vary significantly between both groups, but numerical differences were observed, with an elevated rate of each in the Biomime group (except for major bleeding).




Figure 3 - Subgroup interaction analysis of TVF at one-year follow up (vessel size, age > 70, sex, DM, post-dilatation, max inflation, stent length). DM: diabetes mellitus, LVEF: left ventricular ejection fraction, TVF: target vessel failure.

Our findings align with those of previous trials. For example, the BIOSCIENCE trial showed that STEMI patients receiving the Orsiro Ultra-Thin SES experienced a lower rate of target lesion failure (TLF) than those treated with the Xience EES (3.3% vs. 8.7%, $p = 0.024$ at 12 months) [11, 12]. In a subgroup assessment of the CENTURY II trial involving approximately 264 high-risk ACS patients, TVF at 24 months occurred in 6.3% of those medicated with Biodegradable Polymer SES (BP-SES), compared to 9.4% of patients treated with a Permanent Polymer Everolimus Eluting Stent (PP-EES). [11, 12]

In the present study, Biomime was non-inferior to Ultimaster with regards to TVF (10.9% versus 8.4%) (RR [95% CI]: 1.296 [0.677–2.482], $P = 0.432$, and PNI = 0.059).

Subgroup analysis suggested a potential advantage and supported the use of Ultimaster over the Biomime for TVF in small vessels (< 2.75 mm). In contrast, cases managed using the Orsiro Ultrathin Stent had a decreased rate of TLR in small-vessel disease than the other treatment groups, according to the BIORESORT trial [1, 13]. However, no differences were documented in the five-year rate of TLF between ultra-thin-strut and thin-strut DES in the subgroup analysis of the BIOSCIENCE trial. [1, 14]

In the meriT-V trial, although the Biomime group showed a decreased rate of MACE compared to the Xience Everolimus-Eluting Stent group (EESs) (2.98% vs. 7.14%; $P = 0.13$), but the difference was not statistically significant. [2]

In the current study, MACE rates were higher, but the difference was not of significance (16.39% for Biomime vs. 10.48% for Ultimaster; RR [95% CI]: 1.512 [0.877–2.61], $P = 0.13$, and PNI < 0.001). Similarly, the BIOSCIENCE trial comparing a biodegradable polymer SES (BP-SES) and DP-EES in PPCI patients found no significant differences in the composite endpoints. [15]

Regarding LLL, the present study demonstrated that Biomime SES (0.34 ± 0.4 mm) were non-inferior to Ultimaster SES (0.36 ± 0.4 mm) (difference [95% CI]: -0.02 [-0.14 – 0.10], $P = 0.756$, and PNI < 0.001). These results are in keeping with findings from the meriT-V trial, which showed similar but numerically lower results. In-stent LLL was 0.15 ± 0.27 mm in the Biomime SES group and 0.15

± 0.29 in the XIENCE EES group (Diff: -0.006 mm; 95% CI: -0.085 to 0.072 ; $p = 0.87$; p -value for non-inferiority < 0.0001). [2] ORIENT and BIOFLOW-II trials demonstrated lower LLL values for Orsiro Ultrathin Strut DES compared to second-generation DES. [16, 17]

The definite ST rate in this study at 12 months was 4.4% for Biomime and 1.8% for Ultimaster stents (RR [95% CI]: 2.42 [0.653–8.96], $P = 0.171$). While this rate is higher numerically (but not to a statistically-significant degree) than the rate reported in some other trials, such as the MASTER and EXAMINATION trials [4, 18], a potential imbalance in lesion complexity and use of longer stents may have contributed to the higher rate of ST in the Biomime group.

Study limitations included the absence of intravascular imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) due to limited resources. The safety and efficacy of these stents in bifurcation lesions also remain untested in this STEMI population. Finally, non-standardized post-dilatation protocols may have influenced outcomes.

Conclusion

In STEMI cases undergoing PPCI, the Biomime SES showed non-inferiority to the Ultimaster SES regarding TVF and MACE at the one-year follow-up. LLL and restenosis rates were similar in both groups. Thus, Biomime stents offer a suitable option for STEMI patients undergoing PPCI. Longer-term follow-up will be essential to assess very late risks associated with Biomime stents.

Ethics Compliance

We confirm that the study was conducted in compliance with ethical guidelines and that all necessary approvals and consents were obtained.

REFERENCES

1. Leone A, Simonetti F, Avvedimento M, Angellotti D, Immobile Molaro M, Franzone A, et al. Ultrathin struts drug-eluting stents: a state-of-the-art review. *J Pers Med*. 2022;12:13–78.
2. Abizaid A, Kedev S, Kedhi E, Talwar S, Erglis A, Hlinomaz O, et al. Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. *EuroIntervention* 2018;14:1207–14.
3. Stojkovic S, Neskovic AN, Mehmedbegovic Z, Kafedzic S, Ostojic M, Nedeljkovic M, et al. Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. *Fund Clin Pharmacol*. 2015;29:95–05.
4. Valdes-Chavarri M, Kedev S, Neskovic AN, de la Tassa CM, Zivkovic M, Nouche RT, et al. Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: the master study. *EuroIntervention* 2019;14:1836–42.
5. Byrne RA, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). *Eur Heart J Acute Cardiovasc Care* 2024;13:55–161.
6. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). *Circulation* 2018;138:618–51.
7. Khosravani-Rudpishi M, Joharimoghadam A, Rayzan E. The significant coronary tortuosity and atherosclerotic coronary artery disease; What is the relation? *J Cardiovasc Thorac Res*. 2018;10:209–13.
8. Ishibashi S, Sakakura K, Asada S, Taniguchi Y, Jinnouchi H, Tsukui T, et al. Angiographic coronary calcification: A simple predictor of long-term clinical outcomes in patients with acute myocardial infarction. *J Atheroscler Thromb*. 2023;30:990–1001.
9. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized end point definitions for coronary intervention trials: The Academic Research Consortium-2 consensus document. *Circulation* 2018;137:2635–50.
10. Suzuki N, Asano T, Nakazawa G, Aoki J, Tanabe K, Hibi K, et al. Clinical expert consensus document on quantitative coronary angiography from the Japanese association of cardiovascular intervention and therapeutics. *Cardiovasc Interv Th*. 2020;35:105–16.
11. Jiménez VA, Iñiguez A, Baz JA, Valdés M, Ortiz A, Vuilliminet A, et al. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute

Acknowledgements

None.

Competing interests

The authors have no financial or proprietary interests in any material discussed in this article.

List of abbreviations

SES: Sirolimus-eluting stent
STEMI: ST-elevation myocardial infarction
TVF: Target vessel failure
ST: Stent thrombosis
DES: Drug-eluting stent
BMSs: Bare-metal stents
LLL: Late lumen loss
MACE: Major adverse cardiac events
MLD: Minimal lumen diameter.
LV: left ventricular
WMSI: Wall motion score index
DAPT: Dual antiplatelet treatment
ECGs: Electrocardiograms
QCA: Quantitative Coronary Angiography
ARC: Academic Research Consortium

coronary syndromes: The Century II high risk ACS substudy. *Cardiovasc Revasc Med.* 2016;17:355–61.

12. Gherbesi E, Danzi GB. The Ultimaster coronary stent system: 5-year worldwide experience. *Future Cardiol.* 2020;16:251–61.

13. Buiten RA, Ploumen EH, Zocca P, Doggen CJ, Van Der Heijden LC, Kok MM, et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels: a prespecified analysis of the randomized bio-resort trial. *JAMA Cardiol.* 2019;14:659–69.

14. Iglesias JF, Heg D, Roffi M, Tüller D, Noble S, Muller O, et al. Long-term effect of ultrathin-strut versus thin-strut drug-eluting stents in patients with small vessel coronary artery disease undergoing percutaneous coronary intervention: a subgroup analysis of the BIOSCIENCE randomized trial. *Circ Cardiovasc Interv.* 2019;12:80–24.

15. Pilgrim T, Piccolo R, Heg DH, Roffi M, Tüller D, Vuillomenet A, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. *EuroIntervention* 2016;12:1343–54.

16. Kang S-H, Chung W-Y, Lee JM, Park J-J, Yoon C-H, Suh J-W, et al. Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial. *EuroIntervention* 2017;12:1623–31.

17. Windecker S, Haude M, Neumann F-J, Stangl K, Witzenbichler B, Slagboom T, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. *Circ Cardiovasc Interv.* 2015;8:14–41.

18. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. *The Lancet* 2012;380:1482–90.